| 26.89 -1.19 (-4.24%) | 08-24 16:00 | |||||||||||||
|
|
| Short term |   |
|||
| Mid term |  |
|||
| Targets | 6-month : | 32.7 |
1-year : | 35.2 |
| Resists | First : | 28 |
Second : | 30.13 |
| Pivot price | 27.77 |
|||
| Supports | First : | 24.54 |
Second : | 20.42 |
| MAs | MA(5) : | 28.13 |
MA(20) : | 27.65  |
| MA(100) : | 27.29 |
MA(250) : | 36.14 |
|
| MACD | MACD : | 0.7 |
Signal : | 0.9 |
| %K %D | K(14,3) : | 42.7 |
D(3) : | 55 |
| RSI | RSI(14): 49.2 |
|||
| 52-week | High : | 48.25 | Low : | 19.15 |
Price has closed below its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and NEUTRAL in mid-long term.[ AORT ] has closed above bottom band by 27.3%. Bollinger Bands are 38.6% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
| If tomorrow: | Open lower | Open higher |
| High: | 28.19 - 28.32 | 28.32 - 28.46 |
| Low: | 26.38 - 26.54 | 26.54 - 26.71 |
| Close: | 26.58 - 26.85 | 26.85 - 27.11 |
Artivion Inc. is a global company that develops, produces, and supplies medical devices and implantable human tissues. Its product range includes BioGlue, a polymer derived from bovine blood protein combined with a cross-linking agent, utilized in cardiac, vascular, neurological, and pulmonary surgical applications. The company also offers heart preservation services and the PhotoFix bovine pericardial patch, in addition to E-vita Open Plus and E-vita Open Neo devices. For the treatment of aortic vascular conditions, Artivion provides specialized stent graft systems. These include E-xtra design engineering systems for aortic vascular diseases, E-nside as an off-the-shelf solution for thoraco-abdominal disease, E-vita THORACIC 3G for endovascular repair of thoracic aortic aneurysms, E-nya for minimally invasive repair of descending aorta lesions, and the E-tegra system for abdominal aortic aneurysms. Furthermore, its offerings address peripheral and renal artery treatments with the E-ventus BX balloon-expandable stent graft and the E-liac system for aneurysmal iliac arteries and their side branches. The company's diverse portfolio extends to synthetic vascular grafts for use in open aortic and peripheral vascular surgeries, PerClot (an absorbable powdered hemostat for surgical procedures), and cardiac laser therapy products for angina management. Preservation services include CryoVein for femoral veins and CryoArtery for femoral arteries. Artivion also manufactures On-X prosthetic aortic and mitral heart valves, along with the On-X ascending aortic prosthesis. Supplementary devices feature CarbonAid CO2 diffusion catheters and Chord-X ePTFE sutures designed for mitral chordal replacement, as well as ascyrus medical dissection stents. Beyond products, the company offers pyrolytic carbon coating services to other medical device manufacturers. Artivion Inc. serves a broad client base, including physicians, hospitals, other healthcare facilities, and specialists such as cardiac, vascular, thoracic, and general surgeons. Established in 1984 and headquartered in Kennesaw, Georgia, the company adopted the name Artivion Inc. in January 2022, having previously operated as CryoLife, Inc.
Mon, 24 Aug 2026
Have Artivion Insiders Been Selling Stock? - simplywall.st
Thu, 20 Aug 2026
Artivion Inc (AORT) President & CEO James Mackin Sells 70,000 Sh - GuruFocus
Thu, 20 Aug 2026
Insider Selling: Artivion (NYSE:AORT) CEO Sells $2,026,500.00 in Stock - MarketBeat
Wed, 19 Aug 2026
Artivion (NASDAQ: AORT) executive moves to sell 70,000 shares - Stock Titan
Wed, 19 Aug 2026
Why Artivion (AORT) Stock Is Trading Up Today - StockStory
Wed, 19 Aug 2026
Does Revenue Growth Amid New Losses Reshape The Bull Case For Artivion (AORT)? - Sahm
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Neutral |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Underperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NYSE
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Medical - Devices
|
|
| Shares Out | 49 (M) |
| Shares Float | 46 (M) |
| Held by Insiders | 4.3 (%) |
| Held by Institutions | 96 (%) |
| Shares Short | 2,710 (K) |
| Shares Short P.Month | 2,180 (K) |
| EPS | -0.06 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 9.14 |
| Profit Margin | -0.7 % |
| Operating Margin | 9 % |
| Return on Assets (ttm) | 2.5 % |
| Return on Equity (ttm) | -0.8 % |
| Qtrly Rev. Growth | 11.3 % |
| Gross Profit (p.s.) | 6.22 |
| Sales Per Share | 9.66 |
| EBITDA (p.s.) | 1.3 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | 42 (M) |
| Levered Free Cash Flow | 13 (M) |
| PE Ratio | -448.17 |
| PEG Ratio | 643.7 |
| Price to Book value | 2.93 |
| Price to Sales | 2.78 |
| Price to Cash Flow | 31.43 |
| Dividend | 0.02 |
| Forward Dividend | 0 |
| Dividend Yield | 0.1% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|